---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-219420"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2026-05-12T20:10:15+00:00"
generated_at: "2026-05-12T21:12:01.958888+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Q1 2026 net loss $4.1M; cash runway extended; FDA agrees path for tab-cel BLA resubmission

## Summary
- Net loss $4.1M ($0.29 diluted EPS) vs net income $38.0M ($3.50 diluted) in Q1 2025.
- Revenue $0.5M (prior Q1: $98.1M) due to FY2025 one-time tab-cel manufacturing transfer revenue.
- Cash $8.4M at Mar 31; plus $4.8M ATM proceeds post-quarter; runway into mid-2027.
- FDA agreed single-arm ALLELE study with historical control could support tab-cel BLA resubmission; update expected Q3 2026.
- R&D expenses $0.2M (vs $27.4M), G&A $3.6M (vs $11.5M) reflecting cost reductions.

## SEC filing metadata
- accession: 0001193125-26-219420
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2026-05-12T20:10:15+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000119312526219420/0001193125-26-219420-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000119312526219420/atra-20260512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-219420
- JSON: https://secwatch.observer/filing/0001193125-26-219420.json
- Plain text: https://secwatch.observer/filing/0001193125-26-219420.txt

## Key facts
- Earnings Releases
  Atara Biotherapeutics, Inc. reported first quarter 2026 results: revenue $0.5 million, net income net loss of $4.1 million, EPS ($0.29) basic and diluted loss per share.
  - Period: first quarter 2026
  - Revenue: $0.5 million
  - Net income: net loss of $4.1 million
  - EPS: ($0.29) basic and diluted loss per share
  - Result: reported results
  source text: 31, 2025. • Net cash used in operating activities was $3.1 million for the first quarter 2026, as compared to $28.1 million in the same period in 2025. • Total revenues were $0.5 million for the first quarter 2026, as compared to $98.1 million for the same period in 2025. The prior ‐ year period reflects a one ‐ time acceleration of revenue recognized upon the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000119312526219420/0001193125-26-219420-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.